Please assess the completion status of the following clinical trial:

Trial Title: Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age from 18 to 64 years at entry~2. Patients with mitral and/or aorthic valve bioprosthesis for at least 3 months postoperatively~3. There is 12-lead electrocardiogram documented AF on the day of screening or randomization; or a 24-hour Holter electrocardiogram recording showing AF episodes postoperatively~4. Brain computed tomography scan without hemorrhage or findings of acute cerebral infarction on the last 2 days of screening~5. Exclusion of atrial thrombus or valve prosthesis thrombosis by transesophageal echocardiograph on the last 2 days of screening~6. Written, informed consent~Exclusion Criteria:~1. Previous hemorrhagic stroke~2. Ischemic stroke in the last 6 months~3. Severe renal impairment (creatinine clearance rates \< 30 ml/min)~4. Active liver disease (any etiology)~5. Concomitant use of any antiplatelet (aspirin, clopidogrel, prasugrel, ticagrelor, ticlopidine, etc)~6. Increased risk of bleeding (congenital or acquired)~7. Uncontrolled hypertension~8. Gastrointestinal hemorrhage within the past year~9. Anemia (hemoglobin level \<10 g/dL) or thrombocytopenia (platelet count \< 100 × 109/L)~10. Active infective endocarditis~11. Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Dabigatran (Type: EXPERIMENTAL): Dabigatran 110 mg BID
- Warfarin (Type: ACTIVE_COMPARATOR): Warfarin adjusted-dose

Based on this trial design, predict the completion outcome and termination type (if applicable).